[HTML][HTML] Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes

SFB van der Horst, ESL Martens, PL den Exter… - Thrombosis research, 2023 - Elsevier
Background Idarucizumab has been approved to reverse the anticoagulant effect of
dabigatran. However, there is little knowledge of the effectiveness and safety of …

[HTML][HTML] Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

N Gendron, P Billoir, V Siguret, V Le Cam-Duchez… - Thrombosis …, 2024 - Elsevier
Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients
requiring rapid neutralization is also increasing in case of major bleedings or urgent …

Idarucizumab for emergency reversal of the anticoagulant effects of dabigatran: final results of a Japanese Postmarketing surveillance study

M Yasaka, H Yokota, M Suzuki, H Asakura… - Cardiology and …, 2023 - Springer
Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the
anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which …

[HTML][HTML] Cardiac Tamponade and Duodenal Hemorrhage Caused by Inappropriate Use of Dabigatran in a Patient With End-Stage Renal Failure: A Case Report

M Hayashida, M Suzuki, Y Nakata, H Kakita, H Eizawa - Cureus, 2024 - ncbi.nlm.nih.gov
A 72-year-old man with end-stage renal failure, receiving 220 mg of dabigatran for chronic
atrial fibrillation, was admitted with generalized edema and shortness of breath. Cardiac …

[引用][C] Part I: Interactive case: Life‐threatening bleeding caused by anticoagulants

EJ Owen - Journal of the American College of Clinical …, 2023 - Wiley Online Library
ACCP members may earn up to a total of 3.0 CPE hours by submitting the required posttests
for ACPE and BCPS recertification credit. Posttest access can be purchased for $29.95 at …